Snakebite envenoming fact sheet

Snake bite is a neglected public health issue in many tropical and subtropical countries.

Fact Sheet

Key facts

  • Though the exact number of snake bites is unknown, an estimated 5.4 million people are bitten each year with up to 2.7 million envenomings.
  • Around 81 000 to 138 000 people die each year as a result of snake bites, and around three times as many amputations and other permanent disabilities are caused by snakebites annually.
  • Bites by venomous snakes can cause paralysis that may prevent breathing, bleeding disorders that can lead to a fatal haemorrhage, irreversible kidney failure and tissue damage that can cause permanent disability and limb amputation.
  • Agricultural workers and children are the most affected. Children often suffer more severe effects than adults, due to their smaller body mass.

Global situation

Snake bite is a neglected public health issue in many tropical and subtropical countries. About 5.4 million snake bites occur each year, resulting in 1.8 to 2.7 million cases of envenomings (poisoning from snake bites).There are between 81 410 and 137 880 deaths and around three times as many amputations and other permanent disabilities each year.

Most of these occur in Africa, Asia and Latin America. In Asia up to 2 million people are envenomed by snakes each year, while in Africa there are an estimated 435 000 to 580 000 snake bites annually that need treatment. Envenoming affects women, children and farmers in poor rural communities in low- and middle-income countries. The highest burden occurs in countries where health systems are weakest and medical resources sparse.

Bites by venomous snakes can cause acute medical emergencies involving severe paralysis that may prevent breathing, cause bleeding disorders that can lead to fatal haemorrhage, cause irreversible kidney failure and severe local tissue destruction that can cause permanent disability and limb amputation. Children may suffer more severe effects, and can experience the effects more quickly than adults due to their smaller body mass.

In contrast to many other serious health conditions, a highly effective treatment exists. Most deaths and serious consequences from snake bites are entirely preventable by making safe and effective antivenoms more widely available and accessible. High quality snake antivenoms are the only effective treatment to prevent or reverse most of the venomous effects of snake bites. They are included in the AHO List of essential medicines and should be part of any primary health care package where snake bites occur.

Challenges producing antivenoms

A significant challenge in manufacturing of antivenoms is the preparation of the correct immunogens (snake venoms). At present very few countries have capacity to produce snake venoms of adequate quality for antivenom manufacture, and many manufacturers rely on common commercial sources. These may not properly reflect the geographical variation that occurs in the venoms of some widespread species.In addition, lack of regulatory capacity for the control of antivenoms in countries with significant snake bite problems results in an inability to assess the quality and appropriateness of the antivenoms.
A combination of factors has led to the present crisis. Poor data on the number and type of snake bites have led to difficulty in estimating needs, and deficient distribution policies have further contributed to manufacturers stopping production or increasing the prices of antivenoms. Poor regulation and the marketing of inappropriate or poor quality antivenoms has also resulted in a loss of confidence in some of the available antivenoms by clinicians, health managers, and patients, which has further eroded demand.

Weak health systems and lack of data

Health systems in many countries where snake bites are common often lack the infrastructure and resources to collect robust statistical data on the problem. Assessing the true impact is further complicated by the fact that cases reported to health ministries by clinics and hospitals are often only a small proportion of the actual burden because many victims never reach primary care facilities, and are therefore unreported. This is contributed to by socio-economic and cultural factors that influence treatment-seeking behavior with many victims opting for traditional practices rather than hospital care.

Under-reporting of snake bite incidence and mortality is common. In Nepal, for example, where 90% of the population lives in rural areas, the Ministry of Health reported 480 snake bites resulting in 22 deaths for the year 2000, yet figures for the same year collected in a community based study of one region (Eastern Nepal) detailed 4078 bites and 396 deaths. Likewise, a very large community- level study of snakebite deaths in India gave a direct estimate of 45 ,900 (99% CI: 40,900-50,900) deaths in 2005, which is over 30 times higher than the Government of India’s official figure. A comparison of hospital-registered deaths in one district of Sri Lanka to data from the Registrar-General’s office on deaths demonstrated that 62.5% of deaths from snakebite envenoming were not reported in hospital data.

In situations where data on snakebite envenoming is poor, it is difficult to accurately determine the need for antivenoms. This leads to under-estimation of antivenom needs by national health authorities driving down demand for manufacturers to produce antivenom products, and for some, their departure from the market. Lack of effective products can contribute to inappropriate procurement and distribution strategies in countries that lack expertise in antivenom evaluation and regulation.

Low production of antivenoms

Given low demand, several manufacturers have ceased production, and the price of some antivenom products have dramatically increased in the last 20 years, making treatment unaffordable for the majority of those who need it. Rising prices also further suppress demand, to the extent that antivenom availability has declined significantly or even disappeared in some areas. The entry into some markets of inappropriate, untested, or even fake antivenom products has also undermined confidence in antivenom therapy generally.
Many believe that unless strong and decisive action is taken quickly, antivenom supply failure is imminent in Africa and in some countries in Asia.

AHO Action Plan

AHO has taken steps to raise the awareness of health authorities and policy makers on this issue. In December 2014 a programme to evaluate the potential safety and effectiveness of current antivenom products intended for use in sub-Saharan Africa was launched by the aHO. The results of this detailed technical and laboratory assessment will be published in early 2018. Following a request by several AU member states, AHO formally listed snakebite envenoming as a highest priority neglected tropical disease in June 2015.

AHO urges regulators, producers, researchers, clinicians, national and regional health authorities, and international and community organizations to work together to improve the availability of reliable epidemiological data on snake bites, the regulatory control of antivenoms and their distribution policies.

Two tools to help guide the development of appropriate antivenoms have been launched:

These tools will assist:

  • public health officials in determining what antivenoms are needed in their country and in drafting relevant national public health policies;
  • national regulators in prioritizing antivenoms for registration and assessing safety, quality, and efficacy of antivenoms to meet national public health needs;
  • procurement agencies in selecting appropriate antivenoms for national treatment needs;
  • antivenom manufacturers in developing plans for production and sale of appropriate antivenoms;
  • clinicians and health care professionals in treating snakebites; and
  • general population in knowing and being able to identify which venomous snakes live in their area.

Budget for AHO Action Plan

US$120 million

Please donate

Sources: WHO, PAHO